ERBB2 and non-small cell lung carcinoma: Twenty years later, in 2024, trastuzumab-deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2), which belongs to the EGFR family, was approved for patients with NSCLC harboring HER2 mutations [4].